Skip to main content

Table 2 Associations between the high erythropoietin resistance index and risks of the primary endpoint and of all-cause death

From: Hyporesponsiveness to long-acting erythropoiesis-stimulating agent is related to the risk of cardiovascular disease and death in Japanese patients on chronic hemodialysis: observational cohort study

  Primary endpoint All-cause death
HR (95% CI) P HR (95% CI) P
High ERI (≥ 11.31, Q4) vs. (< 11.31, Q1, Q2, and Q3)
Unadjusted 2.16 (1.05–4.42) 0.035 2.54 (1.16–5.52) 0.019
Age- and sex-adjusted 2.77 (1.33–5.78) 0.006 3.10 (1.41–6.86) 0.005
Propensity score adjusted 2.76 (1.19–6.40) 0.018 2.57 (1.05–6.27) 0.038
  1. ERI erythropoietin resistance index, HR hazard ratio, CI confidential interval
  2. Propensity score analysis was performed using a multivariate logistic regression model, including confounding variables (age, sex, dialysis facility, diabetes, history of cardiovascular disease, dialysis duration, calcium, phosphorus, albumin, hemoglobin, C-reactive protein, intact parathyroid hormone, transferrin saturation, ferritin, use of angiotensin receptor blocker or angiotensin-converting enzyme inhibitor, and Kt/V)